4G/5G and A-844G Polymorphisms of Plasminogen Activator Inhibitor-1 Associated with Glioblastoma in Iran - a Case- Control Study

Background: Glioblastoma is a highly aggressive and malignant brain tumor. Risk factors are largely unknownhowever, although several biomarkers have been identified which may support development, angiogenesis andinvasion of tumor cells. One of these biomarkers is PAI-1. 4G/5G and A-844G are two common polymorphismsin the gene promotor of PAI 1 that may be related to high transcription and expression of this gene. Studies haveshown that the prevalence of the 4G and 844G allele is significantly higher in patients with some cancers andgenetic disorders. Materials and
Methods: We here assessed the association of 4G/5G and A-844G polymorphismswith glioblastoma cancer risk in Iranians in a case-control study. All 71 patients with clinically confirmed and140 volunteers with no history and symptoms of glioblastoma as control group were screened for 4G/5G andA-844G polymorphisms of PAI-1, using ARMS-PCR. Genotype and allele frequencies of case and controlgroups were analyzed using the DeFinetti program.
Results: Our results showed significant associations between4G/5G (p=0.01824) and A-844G (p = 0.02012) polymorphisms of the PAI-1 gene with glioblastoma cancer riskin our Iranian population.
Conclusions: The results of this study supporting an association of the PAI-1 4G/5G(p=0.01824) and A-844G (p = 0.02012) polymorphisms with increasing glioblastoma cancer risk in Iranianpatients.